Pathos AI Partners with AstraZeneca to Advance AZD4241 for ER+ Breast Cancer
NEW YORK, Aug. 4, 2026 Pathos AI announced a collaboration and co-exclusive licensing agreement with AstraZeneca to advance AZD4241,...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NEW YORK, Aug. 4, 2026 Pathos AI announced a collaboration and co-exclusive licensing agreement with AstraZeneca to advance AZD4241,...
LILLE & PARIS, France, Aug. 4, 2026 4Moving Biotech (4MB) announced the completion of patient enrollment in the Phase...
June 10, 2026 – Taipei, Taiwan Caliway Biopharmaceuticals announced new preclinical data demonstrating the potential of its proprietary fat-reduction...
Plainsboro, New Jersey and Bagsværd, Denmark, June 7, 2026 Novo Nordisk has unveiled compelling Phase 3 clinical data for...
HONG KONG and NEW ORLEANS, Louisiana, June 8, 2026 Ascletis Pharma has strengthened its position in the highly competitive...
NEW ORLEANS, Louisiana, June 6, 2026 New data presented at the American Diabetes Association (ADA) 2026 Scientific Sessions have...
GRAND RAPIDS, Mich., June 1, 2026 Cirius Therapeutics has announced the presentation of new clinical data supporting CIR-0602K, its...
Indianapolis, Indiana, USA – May 22, 2026 Eli Lilly and Company announced new clinical analysis from the Phase 3...
NEW TAIPEI CITY, Taiwan, May 18, 2026 Caliway Biopharmaceuticals unveiled new preclinical findings at the European Congress on Obesity...
CAMBRIDGE, Massachusetts; ROTTERDAM, Netherlands; and SHANGHAI, China, May 18, 2026 Harbour BioMed announced promising preclinical data for LET003, its...
